These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22132360)

  • 21. Early improvement predicts 8-week treatment outcome in patients with generalized anxiety disorder treated with escitalopram or venlafaxine.
    Qian M; Shen Z; Lin M; Guan T; Yang J; Li L; Shen X; Yuan Y
    Asia Pac Psychiatry; 2017 Dec; 9(4):. PubMed ID: 29193711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of hair loss with different antidepressants: a comparative retrospective cohort study.
    Etminan M; Sodhi M; Procyshyn RM; Guo M; Carleton BC
    Int Clin Psychopharmacol; 2018 Jan; 33(1):44-48. PubMed ID: 28763345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venlafaxine-induced psychotic symptoms.
    Safeekh AT; Pinto D
    Indian J Psychiatry; 2009; 51(4):308-9. PubMed ID: 20048460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of cardiorespiratory coordination in young women with recurrent major depressive disorder treated with escitalopram or venlafaxine.
    Chang JS; Ha K; Yoon IY; Yoo CS; Yi SH; Her JY; Ha TH; Park T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):136-42. PubMed ID: 22699029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial.
    Jha MK; Minhajuddin A; Gadad BS; Chin Fatt C; Trivedi MH
    Pharmaceuticals (Basel); 2019 Dec; 12(4):. PubMed ID: 31861074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients.
    Song HR; Jung YE; Wang HR; Woo YS; Jun TY; Bahk WM
    Psychiatry Clin Neurosci; 2012 Aug; 66(5):457-9. PubMed ID: 22834666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Boulton DW; Balch AH; Royzman K; Patel CG; Berman RM; Mallikaarjun S; Reeves RA
    J Psychopharmacol; 2010 Apr; 24(4):537-46. PubMed ID: 18832427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders.
    Lam RW; Annemans L
    Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):559-76. PubMed ID: 20528319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escitalopram for the treatment of major depression and anxiety disorders.
    Höschl C; Svestka J
    Expert Rev Neurother; 2008 Apr; 8(4):537-52. PubMed ID: 18416657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escitalopram therapy for major depression and anxiety disorders.
    Baldwin DS; Reines EH; Guiton C; Weiller E
    Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Novel Antidepressants on Cardiac
    Werner RA; Kobayashi R; Javadi MS; Köck Z; Wakabayashi H; Unterecker S; Nakajima K; Lapa C; Menke A; Higuchi T
    J Nucl Med; 2018 Jul; 59(7):1099-1103. PubMed ID: 29496989
    [No Abstract]   [Full Text] [Related]  

  • 33. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.
    Kirino E
    Patient Prefer Adherence; 2012; 6():853-61. PubMed ID: 23271894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unique mechanism of action for escitalopram: does it hold the promise?
    Kasper S
    Int J Psychiatry Clin Pract; 2004; 8 Suppl 1():15-8. PubMed ID: 24930684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine.
    Gahr M; Hiemke C; Kölle MA
    Front Psychiatry; 2020; 11():32. PubMed ID: 32116847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case Report of Fluoxetine- and Venlafaxine-Induced Hair Loss.
    O'Bryan EC; Albanese RP
    Prim Care Companion J Clin Psychiatry; 2004; 6(4):181. PubMed ID: 15361923
    [No Abstract]   [Full Text] [Related]  

  • 37. Current treatment options: relief of symptoms and ultimate recovery.
    Kennedy SH
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 1():22-6. PubMed ID: 24931540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of escitalopram and severity of depression: new data].
    Spadone C
    Encephale; 2009 Dec; 35(6):577-85. PubMed ID: 20004289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.